

RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

Tryptophan 2,3-dioxygenase (TDO) inhibitors : Identification of new scaffolds using virtual screening

Moineaux, Laurence; Charlier, Caroline; Dolusic, Eduard; Larrieu, Pierre; Pilotte, Luc; Colau, Didier; Stroobant, Vincent; Galleni, Moreno; Masereel, Bernard; Van den Eynde, Benoît; Wouters, Johan; Frédérick, Raphaël

Publication date:
2010

Document Version
Early version, also known as pre-print

[Link to publication](#)

Citation for published version (HARVARD):

Moineaux, L, Charlier, C, Dolusic, E, Larrieu, P, Pilotte, L, Colau, D, Stroobant, V, Galleni, M, Masereel, B, Van den Eynde, B, Wouters, J & Frédérick, R 2010, 'Tryptophan 2,3-dioxygenase (TDO) inhibitors : Identification of new scaffolds using virtual screening', Journée scientifique de la Société royale de chimie (SRC), Gembloux, Belgium, 14/10/10 pp. Abstracts, Journée scientifique de la Société royale de chimie (SRC), Gembloux, Belgium, 14 October 2010.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

SYNTHESIS, STRUCTURAL AND ENZYMATIC STUDY OF VINYL-1H-INDOLE ANALOGUES AS POTENTIAL INHIBITORS OF TRYPTOPHAN 2,3- DIOXYGENASE (TDO), A TARGET IN ANTICANCER IMMUNOTHERAPY

Laurence Moineaux,^a Caroline Charlier,^a Eduard Dolušić,^a Pierre Larrieu,^b Luc Pilotte,^b Didier Colau,^b Vincent Stroobant,^b Moreno Galleni,^c Bernard Masereel,^a Benoît Van den Eynde,^b Johan Wouters,^a Raphaël Frédérick^a

^a Drug Design and Discovery Center, University of Namur (FUNDP), 61 Rue de Bruxelles, B-5000 Namur, Belgium; ^b Ludwig Institute for Cancer Research, de Duve Institute, Université Catholique de Louvain, 74 Avenue Hippocrate B-1200 Brussels, Belgium; ^c Center for Protein Engineering (CIP), University of Liège, Institut de Chimie B6, Sart-Tilman, Liège, Belgium

Laurence.moineaux@fundp.ac.be; Raphael.frederick@fundp.ac.be

Immunotherapy is a promising novel strategy for cancer therapy. It consists of the therapeutic vaccination of cancer patients to stimulate their (natural) immune system against cancer cells. This approach, however, showed limited efficacy in vivo. Cancer cells are actually able to develop enzymatic mechanisms allowing tumours to resist or escape the immune rejection. Among the enzymes involved, the indoleamine 2,3-dioxygenases IDO and TDO represents potential actors.[1-3] These enzymes catalyse the rapid degradation of tryptophan (Trp) through the kynurenine (KYN) pathway to form quinolinic acid (QA). This results in a local Trp depletion that severely affects the proliferation of T lymphocytes and is thereby profoundly immunosuppressive.




Figure: Metabolism of L-tryptophan to N-formyl-L-kynurenine catalyzed by IDO or TDO.

This project was funded in part by Télévie (FNRS grant 7.4.543.07) and led in collaboration with the team of Pr Benoît Van Den Eynde (LICR, UCL) and Pr Moreno Galeni (CIP, ULG) aims at developing novel TDO inhibitors using a rational approach. These inhibitors will allow a better understanding of the role of TDO in the phenomenon of immunosuppression, especially in cancerous tumors.

A series of vinyl-1H-indoles has been synthesized and their inhibitory potential has been evaluated on TDO of *Ralstonia metallidurans* (rmTDO) overexpressed in *E.coli* and purified by affinity chromatography. Crystallographic structure of some analogues was obtained and used as starting point for a docking study of these inhibitors in a model of humanized rmTDO. These data allow better understanding of how this family of inhibitors interact with TDO. This process is presented on this poster.

References:

- 1) Uyttenhove, C., and *al.*, (2003), **Nat Med**, 9, 1269-1274
- 2) Van den Eynde, B., and *al.*, (2009), U.S. application S.N.:61/247,372.
- 3) Batabyal D. and *al.*, (2007), **JACS**, 129, 15690-15701